September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Hyperbaric Oxygen Therapy for Central Retinal Artery Occlusion
Author Affiliations & Notes
  • Sruti Sarvari Akella
    Stony Brook University, Fishkill, New York, United States
  • Ronald C Gentile
    Winthrop-University Hospital, Mineola, New York, United States
    The New York Eye and Ear Infirmary at Mount Sinai, New York, New York, United States
  • Jay Yasen
    Winthrop-University Hospital, Mineola, New York, United States
  • Sarah Cherian
    Winthrop-University Hospital, Mineola, New York, United States
  • Scott Gorenstein
    Winthrop-University Hospital, Mineola, New York, United States
  • Nazanin Barzideh
    Winthrop-University Hospital, Mineola, New York, United States
  • Footnotes
    Commercial Relationships   Sruti Akella, None; Ronald Gentile, None; Jay Yasen, None; Sarah Cherian, None; Scott Gorenstein, None; Nazanin Barzideh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2051. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sruti Sarvari Akella, Ronald C Gentile, Jay Yasen, Sarah Cherian, Scott Gorenstein, Nazanin Barzideh; Hyperbaric Oxygen Therapy for Central Retinal Artery Occlusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2051.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Central retinal artery occlusions (CRAO) have a poor prognosis despite treatment. The treatment and treatment window are controversial, with no consensus on the best way to manage such patients. The purpose of our study was to evaluate our experience using hyperbaric oxygen therapy (HBO) to treat CRAOs.

Methods : A retrospective chart review of consecutive patients with a diagnosis of CRAO treated with HBO over a 5-year period at one hospital was performed. HBO was performed within 24 hours of vision loss. Diagnosis was confirmed on ophthalmoscopic examination. Snellen visual acuities were recorded before and after HBO and converted to decimal equivalents for statistical analysis.

Results : 6 patients with a CRAO were identified with one patient having cilio-retinal artery involvement. Mean time of HBO from vision loss was 11.5 hours (range 2.5-15.0 hours). Mean decimal equivalent visual acuities before and after HBO were 0.0015 (range NLP to HM) and 0.013 (range NLP to 20/300), respectively (t-test, p=0.3621). Of the 3 patients whose vision improved post-HBO, two improved by 1 line and 1 by two lines. Mean time to HBO treatment for those patients that improved versus those that did not was 9.83 hours versus 13.17 hours, respectively (t-test, p=0.4779).

Conclusions : Visual acuity improved in 50% of CRAO eyes treated with HBO and those patients with visual acuity improvement had earlier HBO treatment compared to those that did not have visual acuity improvement. Despite these positive findings in favor of HBO and earlier HBO, the differences were not found to be statistically significant. Further investigation is needed to further clarify the role of HBO in the treatment of CRAO, including the most effective timing for this treatment.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.